Angiology
Protein tyrosine phosphatase inhibition improves vascular endothelial dysfunction
Published in Obesity and Diabetes Week, April 17th, 2006
According to a report from India, "The study has been designed to investigate the effect of Bis-(maltolato) oxovanadium (BMOV), an inhibitor of protein tyrosin phosphatase (PTPase), in diabetes mellitus and hyperhomocysteinemia-induced vascular endothelial dysfunction."
D.I. Shah and M. Singh working with Punjabi University described their procedure, "Streptozotocin (55 mg kg-1, i.v.) and methionine (1.7% w/w, p.o., 4 weeks) were administered to rats to produce diabetes mellitus (serum glucose >140...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Control
Moderate exercise improved whole-day glycemic control in obese with type 2 diabetes - Diet & Nutrition
Chronic high-fat and high-sucrose diets differentially affect glucose intolerance in mice - Metabolic Syndrome Risk Factors
Small dense ow-density lipoprotein might be a risk factor for metabolic syndrome development - Obesity Pathogenesis
Adipocyte fatty acid-binding protein is obesity and metabolic syndrome-related biomarker - Obesity Pathogenesis
Hepatic leptin resistance due to PTP1B overexpression may lead to diabetes and obesity - Angiology
Mesenteric fat thickness is linked to metabolic syndrome and cardiovascular disease risk - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
